home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.54 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

31 32 Next >

Is It Too Late to Buy Viking Therapeutics Stock? ↗

November 17, 2024

Via The Motley Fool

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On. ↗

November 16, 2024

Mergers and acquisitions could make a comeback with Trump headed back to Washington.

Via The Motley Fool

Topics Government

Market Whales and Their Recent Bets on VKTX Options ↗

November 15, 2024

Via Benzinga

Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead? ↗

November 15, 2024

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? ↗

November 13, 2024

Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.

Via The Motley Fool

Unpacking the Latest Options Trading Trends in Viking Therapeutics ↗

October 29, 2024

Via Benzinga

Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today ↗

October 28, 2024

Via Benzinga

3 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 24, 2024

Via Benzinga

Is Viking Therapeutics a Buy on the Dip? ↗

November 10, 2024

Viking stock has slipped more than 20% from its peak.

Via The Motley Fool

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗

November 08, 2024

A Fed rate cut and a slew of big earnings reports filled out a busy week.

Via Investor's Business Daily

Topics Economy Government

4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move ↗

November 08, 2024

All signs are pointing toward its continued success.

Via The Motley Fool

Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag ↗

November 07, 2024

The company's latest presentation supports the idea that its lead program will make billions.

Via The Motley Fool

An Overview of Viking Therapeutics's Earnings ↗

October 22, 2024

Via Benzinga

Is Viking Therepautics a Buy Now? ↗

November 05, 2024

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Via The Motley Fool

Why Viking Therapeutics Stock Plummeted After Soaring Today ↗

November 04, 2024

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?

Via The Motley Fool

Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety ↗

November 04, 2024

Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes.

Via Benzinga

Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data ↗

November 03, 2024

The biotech reported strong weight loss for higher doses of its experimental obesity pill.

Via Investor's Business Daily

MarketBeat Week in Review – 10/28 - 11/1

November 02, 2024

Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment

Via MarketBeat

Topics Artificial Intelligence Economy

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗

November 01, 2024

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

Via Investor's Business Daily

Viking Therapeutics Stock: A Pre-Election Bet Worth Considering

October 31, 2024

Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors

Via MarketBeat

This High-Flying Stock Just Became a Better Buy ↗

October 31, 2024

It might not be too late to get in on the party.

Via The Motley Fool

Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution? ↗

October 27, 2024

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

Via The Motley Fool

S&P 500, Nasdaq Rise Sharply Ending 3-Day Losing Streak; Viking Therapeutics Surge, While Capri’s Shares Slump ↗

October 25, 2024

US benchmark equity averages rose on Friday as the market ended a three-day losing streak.

Via Talk Markets

Topics Stocks

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review ↗

October 25, 2024

The major indexes were mixed for the week.

Via Investor's Business Daily

Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday ↗

October 24, 2024

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.

Via The Motley Fool

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday ↗

October 24, 2024

Via Benzinga

How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet ↗

October 24, 2024

Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss.

Via Investor's Business Daily

3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia) ↗

October 24, 2024

Regardless of who wins the presidency, investors are better off focusing on top growth stocks.

Via The Motley Fool

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com